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Biochemical Diagnosis of Chromafﬁn Cell Tumors in
Patients at High and Low Risk of Disease:
Plasma versus Urinary Free or Deconjugated
O-Methylated Catecholamine Metabolites
Graeme Eisenhofer,1,2* Aleksander Prejbisz,3 Mirko Peitzsch,1 Christina Pamporaki,2 Jimmy Masjkur,2
Natalie Rogowski-Lehmann,4 Katharina Langton,2 Elena Tsourdi,2,5 Mariola Pe˛czkowska,3
Stephanie Fliedner,6 Timo Deutschbein,7 Felix Megerle,7 Henri J.L.M. Timmers,8 Richard Sinnott,9
Felix Beuschlein,4 Martin Fassnacht,7,10 Andrzej Januszewicz,3 and Jacques W.M. Lenders2,8
BACKGROUND: Measurements of plasma or urinary meta-
nephrines are recommended for diagnosis of pheochro-
mocytoma and paraganglioma (PPGL). What test offers
optimal diagnostic accuracy for patients at high and low
risk of disease, whether urinary free metanephrines offer
advantages over deconjugated metanephrines, and what
advantages are offered by including methoxytyramine in
panels all remain unclear.
METHODS: A population of 2056 patients with suspected
PPGLs underwent prospective screening for disease
using mass spectrometric-based measurements of plasma
free, urinary deconjugated, and urinary free meta-
nephrines and methoxytyramine. PPGLs were con-
firmed in 236 patients and were excluded in others on
follow-up evaluation.
RESULTS: Measurements of plasma free metabolites of-
fered higher (P  0.01) diagnostic sensitivity (97.9%)
than urinary free (93.4%) and deconjugated (92.9%)
metabolites at identical specificities for plasma and uri-
nary free metabolites (94.2%) but at a lower (P 0.005)
specificity for deconjugated metabolites (92.1%). The
addition of methoxytyramine offered little value for uri-
nary panels but provided higher (P  0.005) diagnostic
performance for plasma measurements than either uri-
nary panel according to areas under ROC curves (0.991
vs 0.972 and 0.964). Diagnostic performance of urinary
and plasma tests was similar for patients at low risk of
disease, whereas plasma measurements were superior to
both urinary panels for high-risk patients.
CONCLUSIONS: Diagnosis of PPGLs using plasma or uri-
nary free metabolites provides advantages of fewer false-
positive results compared with commonly measured de-
conjugated metabolites. The plasma panel offers better
diagnostic performance than either urinary panel for pa-
tients at high risk of disease and, with appropriate pre-
analytics, provides the test of choice. Measurements of
methoxytyramine in urine show limited diagnostic utility
compared with plasma.
© 2018 American Association for Clinical Chemistry
Pheochromocytomas and paragangliomas (PPGLs)11 in-
clude adrenal and extraadrenal chromaffin cell tumors
as well as head and neck paragangliomas. The former
catecholamine-producing chromaffin cell tumors must
be considered among large numbers of patients with hy-
pertension and symptoms of catecholamine excess, as
well as for patients at higher risk of disease because of a
hereditary predisposition, the finding of an incidenta-
loma, or a history of PPGLs (1–3 ). Biochemical testing is
crucial for diagnosis of the tumors. To this end, current
clinical practice guidelines stipulate with a high level of
evidence that biochemical screening for PPGLs should
include measurements of plasma free or urinary fraction-
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ated metanephrines (i.e., normetanephrine and meta-
nephrine), with no recommendation concerning prefer-
ence of either test (4 ).
Although some studies have indicated higher accu-
racy of plasma free than urinary fractionated metaneph-
rines for diagnosis of PPGLs (5, 6 ), others have not
(7, 8 ), and all had limitations. None involved head-to-
head comparisons by LC-MS/MS. After introduction by
Lagerstedt et al. in 2002 (9 ), LC-MS/MS now provides
the method of choice for measurements of plasma free
metanephrines as reflected by an international quality
assurance program (10 ), in which 92% of all participants
now use the technology. Among all participating labora-
tories, two-thirds also measure methoxytyramine, the
metabolite of dopamine. Although measurements of
plasma methoxytyramine appear useful (11, 12 ), the
comparative utility of urinarymeasurements of methoxy-
tyramine remains unclear. In this report, the term “meta-
nephrines” is restricted to covering normetanephrine and
metanephrine.
It has been suggested that plasma measurements of
metanephrines suffer from an overabundance of false-
positive results, restricting suitability of the test to pa-
tients at high risk for PPGLs (13 ). That assertion has
since been clarified by findings that sampling blood in
the seated position rather than the recommended supine
position results in a 6-fold increase in false-positive re-
sults (14 ). It remains unclear whether diagnostic accu-
racy of plasma and urinary tests differs among popula-
tions according to differing pretest prevalences and, thus,
risk of PPGLs.
Another consideration in use of tests concerns
whether measurements of metanephrines in urine should
continue to use an acid-hydrolysis deconjugation step or
whether measurements of free metanephrines, without
that step, might offer advantages (15–17). At least for
plasma measurements, the free metanephrines provide
superior diagnostic performance compared with the de-
conjugated metanephrines (18 ). This is because the de-
conjugated metanephrines mainly reflect sulfate conju-
gates produced by a specific sulfotransferase enzyme
localized to gastrointestinal tissues where nearly half of all
norepinephrine is produced and metabolized within the
body (19 ). It remains unclear whether these differences
also offer advantages to urinary free compared with de-
conjugated metanephrines. Substantial production of
dopamine in gastrointestinal tissues (20 ) may similarly
provide advantages to use of free methoxytyramine over
the deconjugated metabolite, but this is also unclear.
Based on the above considerations, the present study
addressed the hypothesis that measurements in plasma
and urine of the free forms of catecholamine O-
methylated metabolites should offer superior perfor-
mance for diagnosis of PPGLs than routinely used
urinary deconjugatedmetabolites.We also examined dif-
ferences in diagnostic performance of the 3 test panels
with and without methoxytyramine and whether test
performancemight differ according to the basis of testing
and relative risk of disease. As initiated in 2011 under a
multicenter prospective protocol, the study aimed to ac-
crue at least 2000 patients, including 200 with PPGLs.
The study involved follow-up to establish a final diagno-
sis; all measurements were by LC-MS/MS; and for the
plasma test, all patients were sampled in the supine posi-
tion according to clinical practice guidelines (4 ).
Study Design and Methods
STUDY POPULATION
The study population included 2056 patients (1011
male) with a median age of 53 years (range, 10–93 years)
screened for PPGLs under a multicenter prospective pro-
tocol as detailed in the Methods section of the Data Sup-
plement that accompanies the online version of this arti-
cle at http://www.clinchem.org/content/vol64/issue11.
In brief, enrollment of patients at 6 European tertiary
medical centers followed 4 criteria establishing suspicion
or risk for PPGLs: (a) signs and/or symptoms of catechol-
amine excess; (b) hereditary risk of PPGL; (c) findings of
an incidentaloma; or (d) history of PPGL. The study
included multiple phases, from screening to follow-up,
and was conducted according to ethics committee-
approved clinical protocols and standard operating pro-
cedures available online (https://pmt-study.pressor.org).
A reference population of 351 normotensive (132 male)
and 239 hypertensive (129 male) volunteers with a me-
dian age of 42 years (range, 18–82 years) was also in-
cluded for establishing reference intervals as covered in
the Methods section of the online Data Supplement. All
participants provided written informed consent.
TUMOR DIAGNOSIS AND FOLLOW-UP
Initial detection of PPGLs was based in most cases on
positive biochemical test results, but follow-up was re-
quired to further confirm or exclude disease in other cases
(see the Methods section of the online Data Supple-
ment). PPGLs in 5 patients were diagnosed at follow-up
1 year after initial biochemical testing. Patients pre-
senting solely with nonchromaffin cell head and neck
paragangliomas were excluded from the analysis. In this
way, 236 patients were finally diagnosed with chromaffin
cell tumors with confirmation achieved by pathological
examination of surgically resected tumors (n  207) or
by functional imaging evidence of disease in cases that
were not surgically resected because of metastatic in-
volvement or refusal of surgery (n  29). Follow-up in-
formation to exclude PPGLs was available in 97% (1768
of 1820) of patients, of which 56% of cases required an
interval of2 years from study entry to exclude disease.
As detailed in the Methods section of the online Data
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Supplement, shorter durations could be accepted in
other patients, particularly those who underwent adrena-
lectomies, imaging studies, or endocrine testing to estab-
lish an alternative diagnosis.
BLOOD AND URINE COLLECTIONS
For blood sampling, patients were required to fast over-
night and to maintain a fully supine position for 30 min
up until the time of the blood draw (10 mL). Blood
samples collected into heparinized tubes were placed on
ice or cool pads at 4 °C before centrifugation to separate
plasma. On the final day of collection, 24-hour urine
specimens were returned to study centers. Urine volumes
were then determined and samples aliquoted. All speci-
mens collected at different study centers were transported
on dry ice to the central analytical laboratory where sam-
ples were assayed.
BIOCHEMICAL ANALYSES
Measurements of plasma and urinary metanephrines
(normetanephrine, metanephrine) and methoxyty-
ramine were performed at a single laboratory using LC-
MS/MS (21, 22 ). For urine specimens, measurements
were performed with and without an acid hydrolysis step,
the latter for measurements of the free metabolites and
the former to convert sulfate-conjugated metabolites
into the free form for measurements of combined free
plus sulfate conjugated (deconjugated) metabolites. As
outlined in the Methods section of the online Data Sup-
plement, data from the reference population were used to
establish upper cutoffs (UCs) of reference intervals for
urinary metabolites and to validate those previously es-
tablished for plasma metabolites, including age-specific
UCs for normetanephrine. All UCs are specified in the
Methods section of the online Data Supplement.
DATA ANALYSES
Diagnostic sensitivity was estimated from the percentage
of true-positive results among both true-positive and
false-negative results for patients with PPGLs.Diagnostic
specificity was estimated from the percentage of true-
negative results among both true-negative and false-
positive results. ROC curves were constructed using lo-
gistic regression with comparisons of areas under the
ROC curves (AUCs) to assess differences in diagnostic
test performance. Positive predictive values (posttest
probability of a positive result) were calculated across
prevalence rates (pretest probability) using positive like-
lihood ratios. Curves relating the prevalence rates and
positive predictive values were constructed according to
relative increases above cutoffs. Statistical analyses were
done using the JMP statistics software package (SAS
Institute).
Results
PLASMA CONCENTRATIONS AND URINARY OUTPUTS OF
O-METHYLATED METABOLITES
Plasma concentrations and urinary outputs of catechol-
amine O-methylated metabolites were similar in the ref-
erence population and patients screened for PPGLs in
whom disease was excluded (Table 1). Methoxytyramine
for both groups showed completely different proportions
relative to normetanephrine andmetanephrine in plasma
compared with urine. Plasma concentrations of free me-
thoxytyramine were much lower (P  0.0001), 20%
those of normetanephrine and metanephrine. In contrast,
urinary outputs of freemethoxytyramine were 32% to 53%
higher (P 0.0001) than outputs of free normetanephrine
and metanephrine. For the deconjugated metabolites, uri-
nary outputs of methoxytyramine were similar to normeta-
nephrine but 72% to 81% higher (P 0.0001) thanmeta-
nephrine, again a divergent pattern compared with plasma.
Among patients with PPGLs, plasma and urinary
free normetanephrine showed similar 9.6- to 10.4-fold
increases above values in patients without tumors, com-
pared with a smaller (P  0.0001) 5.8-fold increase for
urinary deconjugated normetanephrine (Table 1). Meta-
nephrine showed similar 3.9- to 4.0-fold increases for all
3 tests, whereas methoxytyramine showed a larger (P 
0.001) 2.9-fold increase for the plasma test compared
with 1.5- to 1.6-fold increases for urine tests.
As a group, patients screened because of an inciden-
taloma, hereditary risk, or previous disease history had a
3-fold higher (P  0001) prevalence of PPGLs than pa-
tients tested because of signs and symptoms of presumed
catecholamine excess (see Table 4 in the online Data
Supplement). Plasma concentrations and urinary out-
puts of free and deconjugated normetanephrine and
metanephrine were consistently higher (P  0.05)
among patients with tumors of the low than high
PPGL prevalence group (see Table 5 in the online
Data Supplement).
FALSE-NEGATIVE RESULTS
Among the 236 patients with confirmed PPGLs, there
were 5 patients with false-negative results for plasma free
metabolites, including 2 with negative results for both
urinary panels and 2 others with negative results for uri-
nary free metabolites (see Table 1 in the online Data
Supplement). Sixteen other patients had false-negative
results for urinary free or deconjugated metabolites but
positive results for plasma free metabolites, including 11
with negative free metabolite results, 14 with negative
results for deconjugated metabolites, and 9 with negative
results for both urinary panels (see Table 2 in the online
Data Supplement).
The 21 patients with false-negative results for
plasma free, urinary free, or urinary deconjugated metab-
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olites showed numerous differences in how their disease
presented compared with the other 215 patients with
PPGLs. Only 1 of the 21 patients with false-negative
results was tested because of signs and symptoms, a lower
(P  0.0013) proportion than the group with true-
positive results (5% vs 40%). A larger (P  0.0001)
proportion of patients with false-negative than true-
positive results was tested because of hereditary risk or a
history of PPGLs (71% vs 23%). Patients with false-
negative results also were characterized by a higher prev-
alence of metastatic disease (48% vs 13%; P 0.0005),
extraadrenal tumors (43 vs 16%; P  0.0053), and tu-
mors without production of epinephrine as characterized
by no increase in plasma metanephrine (95% vs 42%;
P  0.0001).
As outlined in the Methods section of the online
Data Supplement, all 5 patients in whom PPGLs were
identified after follow-up of 1 year belonged to the
group of 21 patients with false-negative results.
TRUE-POSITIVE VS FALSE-POSITIVE RESULTS
Using UCs optimized to maintain high diagnostic sensi-
tivity with minimal loss of specificity (see Methods sec-
tion in the online Data Supplement), proportions of
true-positive results were 10% and 6% higher (P 
0.005) for plasma and urinary free normetanephrine, re-
spectively, than for urinary deconjugated normetaneph-
rine (Fig. 1, A, D, and G). Conversely, proportions of
false-positive results were 28% and 23% lower (P 
0.05) for plasma and urinary free normetanephrine, re-
spectively, than for urinary deconjugated normetaneph-
rine. Proportions of true- and false-positive results for
metanephrine showed only small differences among test
panels (Fig. 1, B, E, and H).
Among all metabolites, methoxytyramine showed
the largest differences in proportions of true-positive re-
sults for the 3 test panels (Fig. 1, C, F, and I). True-
positive results for urinary deconjugated methoxyty-
ramine were observed in 8% of patients with PPGLs
compared with proportions nearly 2-fold higher (P 
0.0003) for urinary free methoxytyramine and 5.4-fold
higher (P  0.0001) for plasma free methoxytyramine.
Proportions of true-positive results were also 2.8-fold
higher (P  0.0001) for plasma free than urinary free
methoxytyramine (43.3% vs 15.5%).
DIAGNOSTIC SENSITIVITY AND SPECIFICITY
Diagnostic sensitivity of the plasma panel was higher
than for panels of urinary free and deconjugated metab-
olites both with (P  0.01) and without (P  0.05)
inclusion of methoxytyramine (Table 2). Inclusion of
methoxytyramine had little effect on diagnostic sensitiv-
ities of urinary panels but returned positive results for
plasma measurements in 3 patients with otherwise false-
negative results. Diagnostic specificities, with and with-
out inclusion of methoxytyramine, were higher (P 
0.02) for panels of plasma and urinary free metabolites
than deconjugated metabolites.
Differences in diagnostic performance between
plasma and urinary panels diverged after separation of
Table 1. Plasma concentrations (medians and ranges) and urinary outputs of catecholamine O-methylated metabolites in the
reference population and patients with and without PPGLs.
Test panel Reference populationa No PPGL PPGL
Plasma free metabolites n = 586a n = 1820 n = 236
Normetanephrine, pg/mL 62 (18–201) 67 (11–365) 642 (45–25444)
Metanephrine, pg/mL 29 (5–89) 30 (0.2–145) 120 (5–6889)
Methoxytyramine, pg/mL 4.9 (1.4–17.6) 4.8 (0.4–36.7) 14.1 (0.6–11444)
Urine free metabolites n = 580a n = 1756b n = 226b
Normetanephrine, μg/day 21 (4–100) 22 (1–170) 229 (9–3478)
Metanephrine, μg/day 18 (2–61) 16 (0.2–172) 64 (1–3547)
Methoxytyramine, μg/day 33 (4–136) 34 (2–212) 50 (8–3202)
Urine deconjugated metabolites n = 581a n = 1757b n = 226b
Normetanephrine, μg/day 189 (41–803) 212 (26–2678) 1239 (172–21850)
Metanephrine, μg/day 105 (17–446) 108 (1–991) 419 (9–14946)
Methoxytyramine, μg/day 188 (52–2185) 197 (20–2990) 323 (58–13031)
a Inclusion of the reference population in the table is to provide a comparison with patients without PPGLs. Speciﬁed ranges do not indicate the reference intervals that were used,
which are supplied in the onlineData Supplement. Among the 590 subjects of the reference population,measurements of plasma concentrations andurinary outputs ofmetabolites
were not possible in up to 10 patients.
b Urinary measurements were not possible in up to 64 of the 1820 patients without PPGLs and 10 patients with PPGLs. To convert pg/mL to pmol/L and μg/day to nmol/day, divide
values for normetanephrine, metanephrine, and methoxytyramine by 0.1832, 0.1972, and 0.1672, respectively.
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Fig. 1. Plasma concentrations (A–C) and 24-h urinary outputs of free (D–F) and deconjugated (G–I) normetanephrine (A, D, and G),
metanephrine (B, E, and H), and methoxytyramine (G–I) in patients with and without PPGLs.
All data are shown relative toUCs of reference intervals as shownbydashedhorizontal lines. Percentage values in eachpanel showproportions
of positive results for each measurement.
Diagnosis of Pheochromocytoma
Clinical Chemistry 64:11 (2018) 5
patients into the 2 groups at high and low risk of PPGLs.
Diagnostic sensitivities for both urinary panels, but not
the plasma panel, were higher (P  0.01) in patients at
lower risk of disease tested because of signs and symptoms
compared with those at higher risk with incidentalomas,
a previous disease history, or an underlying mutation.
Accordingly, only patients with a high pretest prevalence
of PPGLs showed a higher (P  0.02) diagnostic sensi-
tivity of the plasma than both urinary panels. In contrast,
only patients with a low pretest prevalence of PPGLs
were those in whom diagnostic specificity was higher
(P  0.01) for panels of plasma and urinary free than
deconjugated metabolites.
ROC CURVES
AUCs for individual metabolites showed the most sub-
stantial differences for methoxytyramine, which for the
plasma panel showed higher (P  0.0001) diagnostic
performance than both urinary panels (Table 3). For
normetanephrine, areas were higher for plasma (P 
0.0014) and urinary free (P  0.0162) than deconju-
gatedmeasurements, whereas areas were similar formeta-
nephrine.With models using both normetanephrine and
metanephrine, the plasma panel provided a higher (P 
0.0021) AUC than for measurements of urinary decon-
jugated but not urinary freemetabolites (Fig. 2 and Table
3). With the addition of methoxytyramine, diagnostic
performance of the plasma panel exceeded that for both
panels of urinary free (P  0.0036) and deconjugated
(P 0.0005) metabolites. With separate examination of
patients with low and high pretest prevalence of PPGLs,
differences in diagnostic performance between plasma
and urinary tests disappeared for patients in the low pre-
test prevalence group but remained significant for the
high prevalence group.
POSITIVE PREDICTIVE VALUES
After correction of posttest probabilities of PPGLs ac-
cording to differences in test performance for patients at
low and high risk of PPGLs (see Results section in the
online Data Supplement), posttest probabilities of
PPGLs not only varied according to pretest prevalences
of disease but also according to the test panel and extent
of increases of metabolites above UCs (Fig. 3). Thus, at
high pretest prevalences of 5%, results for the plasma
panel that were 2-fold above UCs indicated a 99%
probability of disease in 80% of patients with PPGLs
comparedwith 96% and 88%probabilities in 75.0% and
66.4% of patients for panels of urinary free and decon-
jugated metabolites, respectively. At lower pretest preva-
Table 2. Diagnostic sensitivities and speciﬁcities of plasma and urinary panels of O-methylated metabolites.
Groupa Sensitivity, % Speciﬁcity, %
All patients (NMN and MN)
Plasma free 96.6 (228/236)b 94.9 (1727/1820)c
Urinary free 92.9 (210/226) 94.5 (1660/1756)c
Urinary deconjugated 92.9 (210/226) 92.8 (1630/1757)
All patients (NMN, MN, and MTY)
Plasma free 97.9 (231/236)b 94.2 (1714/1820)c
Urinary free 93.4 (211/226) 94.2 (1655/1756)c
Urinary deconjugated 92.9 (210/226) 92.1 (1619/1757)
High pretest prevalence (NMN, MN, and MTY)
Plasma free 96.7 (145/150)b 92.8 (569/613)
Urinary free 89.6 (129/144) 92.8 (542/583)
Urinary deconjugated 89.5 (128/143) 91.8 (536/584)
Low pretest prevalence (NMN, MN, and MTY)
Plasma free 100 (86/86) 94.9 (1145/1207)c
Urinary free 100 (82/82)d 95.0 (1114/1173)c
Urinary deconjugated 98.8 (82/83)d 92.3 (1083/1173)
a Data are shown for all patients (All patients) andpatients testedbecause of signs and symptoms (Lowpretest prevalence) or all those testedbecause of hereditary risk, previous history
of PPGL, or an incidentaloma (High pretest prevalence). Data for all patients includes results for plasma normetanephrine (NMN) and metanephrine (MN) considered
together (NMN and MN) or with additional measurements of methoxytyramine (MTY) for all 3 metabolites (NMN, MN, and MTY). NMN, normetanephrine; MN, metaneph-
rine; MTY, methoxytyramine.
b P< 0.05, higher sensitivity of plasma than both urinary panels.
c P< 0.02, higher speciﬁcity of panels for plasma and urinary free metabolites than urinary deconjugated metabolites.
d P< 0.01, higher sensitivity for low than high prevalence group.
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lences of disease, posttest probabilities of PPGLs showed
larger differences between test panels associated with
smaller differences in proportions of patients with pos-
itive test results. Thus, at a 0.5% pretest prevalence of
disease, results for the plasma panel that were2-fold
above UCs indicated a 76% probability of PPGLs in
98.8% of patients with tumors compared with 65%
and 56% probabilities in 95.1% and 92.8% of patients
for respective panels of urinary free and deconjugated
metabolites.
Discussion
Using a fully prospective design with recruitment of
2000 patients, this study provides novel data and im-
portant updates about currently recommended screening
tests for PPGLs. We show that measurements of plasma
free metabolites provide a superior diagnostic test than
routinely used urinary fractionated metabolites, both in
terms of diagnostic sensitivity and specificity, as well as
overall performance as manifest by AUCs.We also estab-
lish that measurements of the free metabolites in urine
provide diagnostic advantages over the deconjugated me-
tabolites, justifying phasing out the hydrolysis step in the
latter test. Furthermore, although measurements of
plasma free methoxytyramine can be useful for diagnosis
of PPGLs, measurements in urine have negligible diag-
nostic value. Finally, the superiority of the plasma over
urinary tests applies principally to patients tested because
of high risk of PPGLs. For patients at lower risk, specif-
ically those tested because of signs and symptoms of pre-
sumed catecholamine excess, urinary and plasma tests
display similarly high performance. This implies that pa-
tients at high risk for PPGLs benefit the most from the
plasma test. In contrast, plasma measurements provide
minimal diagnostic advantages over urinary measure-
ments for symptomatic patients at low risk for PPGLs.
Findings that the plasma free metabolites provide
overall superior diagnostic performance compared with
urinary deconjugated metabolites is not unexpected
when considering the sources of catecholamines and the
pathways of their metabolism (19 ). Similarities and dif-
ferences in diagnostic signal strengths of plasma free vs
urinary free and deconjugated metabolites are thereby
easily explained by differences in their relative tumoral
and nontumoral sources (see Discussion section in the
online Data Supplement). Irrespective of the underlying
biology, the present findings clearly also establish for the
first time that measurements of both urinary free and
deconjugated methoxytyramine provide an inferior
method to assess tumoral production of dopamine com-
pared with plasma free methoxytyramine. This conclu-
sion is consistent with other data indicating that urinary
Table 3. AUCs (with 95% CI) for tests of plasma free vs urinary free and deconjugated metabolites according to individual
metabolites and combinations of metabolites for all patients and patient groups with high and low pretest prevalences of PPGLs.
Plasma free
metabolites
Urinary free
metabolites
Urinary deconjugated
metabolites
All patients
NMNa 0.971 (0.953–0.982)b 0.962 (0.941–0.976)b 0.946 (0.926–0.961)
MNc 0.788 (0.740–0.821) 0.773 (0.729–0.812) 0.788 (0.744–0.826)
MTYd 0.877 (0.849–0.901)e,f 0.713 (0.673–0.750) 0.722 (0.685–0.756)
NMN and MN 0.984 (0.971–0.992)b 0.973 (0.955–0.984) 0.964 (0.944–0.977)
NMN, MN, and MTY 0.991 (0.985–0.995)e,f 0.972 (0.954–0.983) 0.964 (0.944–0.978)
High pretest prevalence
NMN and MN 0.971 (0.949–0.983)b 0.958 (0.930–0.975) 0.945 (0.913–0.966)
NMN, MN, and MTY 0.981 (0.969–0.989)e,g 0.956 (0.927–0.974) 0.944 (0.911–0.965)
Low pretest prevalence
NMN and MN 0.999 (0.996–1.000) 0.999 (0.996–1.000) 0.997 (0.992–0.999)
NMN, MN, and MTY 1.000 (0.999–1.000) 0.999 (0.995–1.000) 0.998 (0.993–0.999)
a Normetanephrine.
b P< 0.02, higher than urinary deconjugated metabolites.
c Metanephrine.
d Methoxytyramine.
e P< 0.001, higher than urinary deconjugated metabolites.
f P< 0.005, higher than urinary free metabolites.
g P< 0.02, higher than urinary free metabolites.
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methoxytyramine has limited utility for identifying
dopamine-producing PPGLs (23 ).
Although the present findings establish overall higher
performance of plasma than urinary metabolites for di-
agnosis of PPGLs, this does not mean that urinary tests
should be abandoned in favor of the plasma test. High
diagnostic performance of the plasma test can only be
achieved with an accurate method of measurement, ap-
propriately established reference intervals, and strict ad-
herence to preanalytical precautions of supine rest and,
for plasma methoxytyramine, an overnight fast before
blood sampling (14, 24–26). Use of inaccurate immu-
Fig. 2. ROC curves for plasma free, urinary free and urinary deconjugated O-methylated metabolites, constructed according to
multivariable logistic regression model combinations of normetanephrine (NMN), metanephrine (MN), and methoxytyramine
(MTY).
Models included all patientswith andwithout PPGLs for NMNandMN in (A) and for NMN,MN, andMTY in (B).Models for all 3metabolites but
restricted to patientswith a highpretest prevalence of PPGLs (i.e., tested because of genetic risk, previous history, or incidentaloma) are shown
in (C), whereas those with a low pretest prevalence of PPGLs (i.e., tested because of signs and symptoms) are shown in (D). Areas under each
of the 3 ROC curves are indicated in each panel.
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noassays and inappropriately established reference inter-
vals in one study resulted in 25% of patients with
PPGLs returning negative results for the plasma test
(27 ). Even with accurate analytical methods, without
supine rest and fasted sampling, diagnostic performance
of the plasma test can be severely compromised to the
same level or less than the urinary test (8, 14 ). Diagnostic
sensitivity can be particularly compromised with refer-
ence intervals established from seated rather than supine
sampling (25, 28 ). Thus, the urinary test may remain
Fig. 3. Relationships of pretest prevalence of PPGLs vs posttest probability of the tumors according to tests of plasma free metab-
olites (A), urinary free metabolites (B), and urinary deconjugated metabolites (C).
Posttest probabilities are shown according to positive results above UCs (1 × UC), positive results with tests for any analyte ≥1.5-fold above
UCs (1.5 × UC) and positive results within tests for any analyte ≥2-fold above UCs (2 × UC). Shaded areas serve to illustrate posttest
probabilities at common pretest prevalences between 0.5% and 5%. Percent values adjacent to shaded areas of each panel represent
proportions of positive results (i.e., diagnostic sensitivities) at the 3 cutoff levels (1, 1.5, and 2 × UC) at both high and low probabilities of
PPGLs, which for values of 1 × UC are according to the data of Table 2.
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preferable for centers that cannot achieve the correct
combination of an accurate analytical method, appropri-
ately established reference intervals, and adherence to
recommended preanalytical precautions of blood
sampling.
As further established, the urinary panels appear ad-
equate for diagnosis of PPGLs among patients with signs
and symptoms of presumed catecholamine excess who
carry a relatively low pretest prevalence of disease. Be-
cause such patients are most likely to be first encountered
at primary and secondary clinical care centers, use of
urinary measurements may be most appropriate for such
centers where adherence to the preanalytical precautions
for blood sampling may be difficult.
For centers where urinary measurements remain
preferable, the present study provides important new
data to support phasing out measurements of deconju-
gated metanephrines in favor of free metanephrines. In
particular, measurements of urinary free metanephrines
provide improved diagnostic specificity and positive pre-
dictive value compared with deconjugated metaneph-
rines. Lack of requirement for an acid hydrolysis step
during sample preparation provides a further benefit. Be-
cause commercially available calibrators and quality con-
trol samples are provided with the metabolites almost
completely present in the free form, another advantage of
the free metabolites is that any variation in the efficiency
of the acid hydrolysis step will not compromise the accu-
racy of results (17, 24 ).
Although urinary tests appear sufficient for diagno-
sis of PPGLs among low-risk symptomatic patients, the
plasma test is clearly preferable for patients at higher risk
of disease, with inclusion of methoxytyramine being par-
ticularly important for patients withmutations of specific
genes or for whom there is risk of recurrent or metastatic
disease (11, 29 ). Because such patients are those most
usually screened at tertiary care centers, these are also the
centers where the plasma panel is particularly important.
With appropriate expert multidisciplinary teams, such
centers provide thebest location for personalized and correct
implementation and interpretation of laboratory tests to ap-
propriately guide patient treatment (4, 30, 31). Supine
blood sampling is crucial.
Although seated sampling has been suggested if su-
pine sampling is carried out after positive results (32 ),
this approach entails an overabundance of false-positive
results, severely eroding positive predictive value (33 )
and incentive to follow up on positive results (34, 35 ). As
shown here, with supine sampling and appropriately es-
tablished reference intervals, a positive result for the
plasma test can provide probabilities of disease reaching
75% for patients of the low-risk group who show in-
creases of any single plasma metabolite 2-fold above
UCs, as observed in nearly 99% of patients with disease
of that group. When combined with positive results that
also include increases in 2 metabolites of the panel, as
observed in 70% of patients with PPGLs, the proba-
bility of disease approaches 100%.
The study has some limitations, including not being
population based, a necessity of study design to recruit
sufficient numbers of patients with disease (see Discus-
sion section in the online Data Supplement). Other lim-
itations, including that 3% of patients without PPGLs
were lost to follow-up and that urinary measurements
were not possible in 4% of all patients, are similarly ad-
dressed in the Discussion section included in the online
Data Supplement.
Despite the above limitations, the study establishes
that with appropriate preanalytical precautions, the
plasma panel provides superior performance for diagno-
sis of PPGLs compared with panels of either urinary free
or deconjugated metabolites. Among the 2 urinary tests,
the advantages of measuring the free over the deconju-
gated metabolites should fuel efforts to phase out the
latter measurements in favor of the former. Although
measurements of urinary free metabolites might be advis-
able when it is not possible to comply with the require-
ments of the plasma test, it must also be appreciated that
urinary methoxytyramine provides negligible diagnostic
value compared with plasma measurements, the latter
being most important for patients at high risk of PPGLs.
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